Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
AIDS Clinical Trials Group
ClinicalTrials.gov Identifier:
NCT00357552
First received: July 25, 2006
Last updated: August 23, 2012
Last verified: August 2012

July 25, 2006
August 23, 2012
January 2008
October 2010   (final data collection date for primary outcome measure)
  • Percentage of Enrolled Participants With Virologic Success at Week 24 on LPV/r Monotherapy [ Time Frame: From study entry to week 24 ] [ Designated as safety issue: No ]
    Virologic success at week 24 on LPV/r monotherapy was defined as remaining on LPV/r monotherapy at week 24 without prior virologic failure. Virologic failure was met with either of these two conditions: (i) failure to suppress HIV-1 RNA to < 400 copies/mL by week 24 or (ii) confirmed HIV-1 RNA >= 400 copies/mL after confirmed HIV-1 RNA < 400 copies/mL.
  • Probability of Grade 3 or 4 Sign or Symptom, or Laboratory Toxicity Over 24 Weeks on Study. [ Time Frame: From study entry to week 24 ] [ Designated as safety issue: Yes ]
    Probability of Grade 3 or 4 sign or symptom, or laboratory toxicity over 24 weeks on study using Kaplan-Meier estimates of the cumulative probability of Grade 3 or 4 sign or symptom, or laboratory toxicity at week 24. Grading of adverse events (signs and symptoms and laboratory toxicities) was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.
  • Virologic success at Week 24 on LPV/r monotherapy
  • time to first new Grade 3 or 4 sign/symptom or laboratory toxicity during LPV/r monotherapy
Complete list of historical versions of study NCT00357552 on ClinicalTrials.gov Archive Site
  • Number of Screened Subjects With at Least One NNRTI, or NRTI-associated Resistance Mutation at A5230 Screening. [ Time Frame: Screening ] [ Designated as safety issue: No ]
    Number of screened subjects with at least one NNRTI, or NRTI-associated resistance mutation. Resistance interpretations used the November 30, 2011 Stanford algorithm.
  • Time to Treatment Failure, Defined as the First Occurrence of Death, Disease Progression, or Virologic Failure. [ Time Frame: Study entry to Week 104 ] [ Designated as safety issue: Yes ]
  • HIV-related Diagnoses and Clinical Events [ Time Frame: Study entry to week 104 ] [ Designated as safety issue: No ]
  • Number of Subjects With at Least One New PI-associated Resistance Mutation at Time of Virologic Failure. [ Time Frame: At time of virologic failure ] [ Designated as safety issue: No ]
    Number of subjects with at least one new PI-associated resistance mutation at time of virologic failure. Resistance interpretations used the May 6, 2009 Stanford algorithm.
  • Percentage of Subjects Reporting Not Skipping Medications in the Last Month. [ Time Frame: Study entry and weeks 2, 4, 8, 12, 16, 20, and 24 ] [ Designated as safety issue: No ]
    The percentage of subjects reporting never missing medications in the last month.
  • Time to First New Grade 3 or 4 Sign or Symptom or Laboratory Toxicity Following LPV/r Intensification [ Time Frame: From LPV/r intensification to week 104 ] [ Designated as safety issue: Yes ]
    Grading of adverse events (signs and symptoms and laboratory toxicities) was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.
  • Level of HIV-1 RNA as Ascertained From Paired DBS and Plasma [ Time Frame: At study entry and weeks 24 and 48 ] [ Designated as safety issue: No ]
  • HIV-1 Viral Sequence as Ascertained From Paired DBS and Plasma [ Time Frame: At study entry and virologic failure ] [ Designated as safety issue: No ]
  • Plasma HIV-1 RNA Levels Less Than 50 Copies/ml From Study Entry to Week 104. [ Time Frame: From study entry to week 104 ] [ Designated as safety issue: No ]
  • Plasma HIV-1 RNA Levels < 400 Copies/mL From Baseline to Week 104 [ Time Frame: From study entry to week 104 ] [ Designated as safety issue: No ]
  • Change in CD4+ Cell Counts From Baseline to Week 104 [ Time Frame: From study entry to week 104 ] [ Designated as safety issue: No ]
  • Patterns of HIV genotypic resistance mutations at screening to A5230
  • time to treatment failure, defined as the first occurrence of death, disease progression, or virologic failure; viral load less than 50 and less than 400 copies/mL from study entry to Week 104; change in CD4 count from study entry to Week 104
  • HIV-related diagnoses and clinical events
  • resistance patterns in the protease gene of participants at the time of virologic failure or treatment intensification
  • drug adherence assessed as number of missed doses over 4-day recall and pill count
  • time to first new Grade 3 or 4 sign/symptom or laboratory toxicity following LPV/r intensification
Not Provided
Not Provided
 
Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy
A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens

Most anti-HIV regimens include a non-nucleoside reverse transcriptase inhibitor (NNRTI); however, some individuals fail on these regimens. The purpose of this study is to evaluate the safety and effectiveness of the protease inhibitor (PI) lopinavir/ritonavir (LPV/r) in HIV infected individuals who are failing an anti-HIV regimen that includes an NNRTI.

Standard effective antiretroviral therapy for HIV infected individuals includes three-drug combinations of two nucleoside reverse transcriptase inhibitors (NRTIs) with either a PI or an NNRTI. However, three-drug regimens may not be ideal in resource-limited settings, where viral load and resistance testing may not be readily available. The purpose of this study is to evaluate the safety and efficacy of the PI LPV/r alone in treatment-experienced, PI-naive HIV infected individuals who are experiencing virologic failure on three-drug regimens.

This study will last 104 weeks. All participants will receive LPV/r twice daily for up to 104 weeks. Participants who experience virologic failure will receive emtricitabine/tenofovir disoproxil fumarate once daily in addition to LPV/r twice daily for the remainder of the study.

There will be 16 study visits for participants on LPV/r monotherapy and 12 study visits for participants who have intensified LPV/r with emtricitabine/tenofovir disoproxil fumarate. Blood collection and clinical assessment will occur at all visits; urine collection and resistance testing will occur at selected visits.

Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
  • Drug: Emtricitabine/Tenofovir disoproxil fumarate
    Once daily
    Other Name: Truvada
  • Drug: Lopinavir/Ritonavir
    Twice daily
    Other Name: Kaletra, Aluvia
Experimental: LPV/r monotherapy
Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir (TDF) once a day will be added to their regimen.
Interventions:
  • Drug: Emtricitabine/Tenofovir disoproxil fumarate
  • Drug: Lopinavir/Ritonavir

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
123
May 2012
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria for Step 1 Participants:

  • HIV infected
  • Continuous treatment with a three-drug, NNRTI-containing regimen for at least 6 months prior to study entry
  • Viral load of 1,000 copies/ml or greater and less or equal to 200,000 copies/ml obtained within 30 days of study entry
  • Negative pregnancy test within 48 hours of study entry
  • Willing to use acceptable forms of contraception for the duration of the study
  • Laboratory values obtained within 30 days of study entry:

    • Hemoglobin greater or equal to 8.0 g/dL
    • Platelet count greater or equal to 50,000/mm3
    • Estimated Creatinine Clearance greater or equal to 60 mL/min x ULN
    • AST (SGOT), ALT (SGPT) and alkaline phosphatase < 3 x ULN
    • Total bilirubin less or equal to 2.5 x ULN
  • Ability and willingness of participant or legal guardian/representative to give informed consent

Inclusion Criteria for Step 2 Participants:

  • Virologic failure on LPV/r monotherapy defined as viral load of 400 copies/ml or greater after 24 consecutive weeks on LPV/r monotherapy OR virologic failure after initial viral suppression on LPV/r monotherapy
  • Estimated creatinine clearance of 60 ml/min or greater
  • Negative pregnancy test within 48 hours of entry into Step 2
  • Willing to use acceptable forms of contraception for the duration of the study

Exclusion Criteria for All Participants:

  • Breastfeeding
  • Known allergy or sensitivity to study drugs
  • Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with study adherence to study requirements
  • History of chronic hepatitis B infection

Exclusion Criteria for Step I Participants:

  • Prior use of any protease inhibitor treatment
  • Acute therapy for any serious medical condition within 14 days of study entry. For ongoing or chronic therapy, the participant must be on the treatment regimen for at least 14 days, and clinically stable prior to entry. If a potential participant has TB and has received treatment for more than 2 weeks, the TB treatment would have to be modified to include a rifabutin-containing regimen. TB compatible syndromes will also be carefully evaluated prior to entry.

Exclusion Criteria for Step 2 Participants:

- Active opportunistic infection, including tuberculosis (TB)

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
India,   Malawi,   South Africa,   Tanzania,   Thailand
 
NCT00357552
ACTG A5230, 1U01AI068636
Yes
AIDS Clinical Trials Group
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)
Study Chair: Nagalingeswaran Kumarasamy, MBBS, PhD Y. R. Gaitonde Centre for AIDS Research and Education
Study Chair: John Bartlett, MD Division of Infectious Diseases, Duke University Medical Center
AIDS Clinical Trials Group
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP